NYSE
$50.75▲ 0.01%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $102.65BShares out 20.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
46- 4d agoPre-market26.10.21 19:146-KKey event#●●●#●●●#●●●
GSK plcBullish
GSK has received US FDA approval for its chronic hepatitis B treatment, Hibsago (bepirovirsen). The drug demonstrated a 19% functional cure rate in phase III trials, significantly outperforming the current standard of care, and will now be available as a new therapeutic option in the US market.…more
$50.75+0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoRegular26.10.20 02:066-KKey event
GSK plc
GSK's Jemperli has received accelerated approval from the US FDA as the first and only immunotherapy for adult patients with MSI-H/dMMR locally advanced rectal cancer. This approval is based on data from the phase II AZUR-1 trial, offering a new treatment approach that may help patients avoid chemotherapy, radiation, and surgery.…more
$50.75+0.01%vs prev closeView filingShare - 6d agoPre-market26.10.19 20:256-KKey event
GSK plc
GSK announced positive global phase Ib data for its B7-H3-targeted ADC, Ris-Rez, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC). The 8 mg/kg dose cohort achieved a 61% objective response rate (ORR) with a manageable safety profile. These findings support the acceleration of the ongoing global phase III EMBOLD SCLC-301 trial.…more
$50.75+0.01%vs prev closeView filingShare
45 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoRegular26.10.21 23:14Bullish#●●●#●●●#●●●
GSK Wins FDA Approval For Chronic Hepatitis B Drug Hibsago
GSK's chronic hepatitis B treatment, Hibsago, received FDA approval after demonstrating significant functional cure rates in Phase 3 trials. However, the drug includes boxed warnings for serious side effects, which may impact its market adoption.…more
$50.75+0.01%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 4d agoOvernight26.10.21 16:34
●●●●●●●● ●●●●● ●●●●●●
HUTCHMED has closed an exclusive licensing agreement with GSK for its KRAS-EGFR inhibitor outside of China. The deal includes an upfront payment of $110 million and potential milestone payments reaching up to $1.185 billion.…more
$50.75+0.01%vs prev closeShareBenzinga - 4d agoRegular26.10.21 04:50
●●●●●●●● ●●●●● ●●●●●●
The FDA has approved Hibsago as the first treatment for adult patients with chronic hepatitis B without cirrhosis. This approval provides a new therapeutic option for the condition and is expected to strengthen the company's market position.…more
$50.75+0.01%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report